PHARMACY

Teva releases limited doses of generic EpiPen

BY Sandra Levy

Teva is offering limited doses of the FDA approved generic version of Mylan’s EpiPen (epinephrine injection) auto-injector 0.3 mg.

Teva’s generic version of the EpiPen Jr auto-injector 0.15 mg and an additional supply of Teva’s generic version of the EpiPen auto-injector 0.3 mg are expected in 2019. The wholesale acquisition cost for the product is $300, Teva said.

Epinephrine injection is used to treat life-threatening, allergic emergencies, including anaphylaxis in people who are at risk for or have a history of serious allergic emergencies. Each device contains a single dose of epinephrine.

“We’re pleased to provide access to epinephrine injection for patients who may experience life threatening allergic emergencies, and we’re fully dedicated toward ensuring additional supply in 2019,” Teva executive vice president and head of North America commercial Brendan O’Grady said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
PHARMACY

Diplomat Pharmacy to ship certain medications in ClimaCell coolers

BY Sandra Levy

Diplomat Pharmacy is switching from expanded polystyrene, or EPS foam, coolers to TemperPack’s ClimaCell coolers for delivery of temperature-sensitive medications.

ClimaCell coolers are fully recyclable at curbside and insulated with renewable materials that can be recycled wherever plastic bags are accepted.

Diplomat’s efforts will help divert more than five tons of plastic from landfills every week by moving away from EPS foam, according to TemperPack. ClimaCell coolers require 94% less energy to manufacture, meaning reduced carbon emissions, according to the company.

“Switching to ClimaCell not only reduces Diplomat’s carbon footprint; it’s also a reflection of our steadfast commitment to patients,” Diplomat chairman and CEO Brian Griffin said. “It’s difficult to dispose of EPS foam responsibly, and our patients have already expressed their excitement about reducing the amount of plastic heading to landfills. This new packaging allows us to be better stewards of t environment while keeping specialty medications at a stable temperature.”

ClimaCell coolers meet International Safe Transit Association standards, meaning they will keep medication at a safe temperature even in extreme weather conditions.

“Our healthcare system relies on petroleum-based plastics, especially EPS foam. Patients don’t think this is sustainable, and neither do we. ClimaCell is the first in a series of high-tech, plant-based technologies that will empower companies like Diplomat to continue improving human health without compromising environmental health. We are honored and excited to support such an innovative company,” TemperPack cofounder James McGoff said.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?
fda-approval-letter
PHARMACY

AbbVie gets FDA clearance for new Venclexta indication

BY Sandra Levy

AbbVie has received the Food and Drug Administration’s nod for Venclexta (venetoclax tablets) in combination with azacitidine, or decitabine, or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia, or AML, in adults age 75 years old or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

“AML is an extremely aggressive and debilitating blood cancer, and outcomes for patients ineligible for intensive chemotherapy are very poor,” AbbVie executive vice president of research and development and chief scientific officer Michael Severino said.”This new approval for Venclexta marks a significant milestone for AbbVie and, more importantly, for patients diagnosed with this deadly disease. We look forward to continuing our work developing Venclexta and advancing treatment options in other aggressive cancers.”

Venclexta is an oral B-cell lymphoma-2 inhibitor. It is now approved for use in two different blood cancers: newly-diagnosed AML and relapsed/refractory chronic lymphocytic leukemia.

The approval in AML is the third provided under priority review by the FDA for Venclexta, which has been granted four Breakthrough Therapy Designations by the FDA.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon's entry would shake up the most?